Brokerages Set bluebird bio, Inc. (NASDAQ:BLUE) PT at $44.60

bluebird bio, Inc. (NASDAQ:BLUE) has earned a consensus rating of “Hold” from the eight brokerages that are covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $44.60.

A number of research analysts have recently weighed in on the company. Wells Fargo & Company dropped their target price on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a report on Monday, February 24th. StockNews.com assumed coverage on shares of bluebird bio in a report on Tuesday. They issued a “sell” rating for the company. Barclays cut their price target on shares of bluebird bio from $40.00 to $8.00 and set an “overweight” rating for the company in a report on Monday, March 31st. Baird R W downgraded shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 21st. Finally, JPMorgan Chase & Co. raised bluebird bio from an “underweight” rating to a “neutral” rating in a research note on Monday, February 24th.

bluebird bio Stock Up 0.7 %

BLUE stock opened at $4.19 on Tuesday. bluebird bio has a twelve month low of $3.56 and a twelve month high of $28.60. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. The stock’s 50 day moving average is $4.29 and its 200-day moving average is $6.84. The firm has a market capitalization of $41.02 million, a PE ratio of -0.11 and a beta of 0.41.

Institutional Trading of bluebird bio

A number of hedge funds have recently modified their holdings of the business. Regeneron Pharmaceuticals Inc. bought a new stake in shares of bluebird bio during the 4th quarter valued at $175,000. Barclays PLC raised its position in bluebird bio by 273.7% in the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after buying an additional 184,605 shares during the last quarter. Geode Capital Management LLC raised its position in bluebird bio by 3.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock worth $2,433,000 after buying an additional 166,771 shares during the last quarter. Finally, State Street Corp boosted its holdings in shares of bluebird bio by 1.1% in the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock worth $1,996,000 after buying an additional 43,382 shares during the last quarter. Institutional investors own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.